# PREPAST CASE REPORT FORM (CRF)

Insurance number:		
Name:		
Date of birth:	Age:	_ years
Gender: Male / Female		
Date (and time) of admisson to the hospital:		

# I. <u>DAY 0 – ADMISSION:</u>

# I/A: <u>Screening:</u>

Inclusion criteria		
Diagnosis of acute pancreatitis:		
- pancreatic type abdominal pain AND	YES	NO
<ul> <li>serum amylase / lipase &gt; 3xULN OR/AND</li> <li>characteristic findings for pancreatitis on US/CT/MR</li> </ul>	YES	NO
Biliary origin: - gallstone(s) and/or sludge on imaging <b>OR/AND</b> - dilated CBD (>8 mm if ≤75 yo, >10 mm if >75 yo) <b>OR/AND</b> - ALT > 2xULN and ALT>AST	YES	NO
Patient age ≥18 years	YES	NO
ERCP is possibile ≤48 hours from onset of pain	YES	NO
Patient was symptom free during last week	YES	NO
Written informed consent is signed	YES	NO
One "NO" is present = DO <u>NOT</u> INCLUDE!		,

Exclusion criteria				
Pregnancy	NO	YES		
Alcoholic or post-ERCP pancreatitis or pancreatic cancer	NO	YES		
Pain onset >48 hours before ERCP	NO	YES		
Liver cirrhosis Child A-C	NO	YES		
INR > 1.6 (uncorrectable by the time of ERCP)	NO	YES		
Pancreatic fluid collections or necrosis at presentation	NO	YES		
Previous sphincterotomy	NO	YES		
One "YES" is present = EXCLUDE!				

Acute cholangitis (modified TG13)			
A: Systemic inflammation:			
- fever (>38 °C) and/or shaking <b>AND</b>	YES	NO	
- laboratory data: evidence of inflammatory response (WBC <4 or >10 G/l and/or CRP≥10 mg/l, etc)	YES	NO	
B: Cholestasis:			
- jaundice (serum bilirubin ≥34.2 μmol/l) <b>OR/AND</b>			
- laboratory data: abnormal LFTs (ALP, GGT, ALT, AST >1.5xULN)	YES	NO	
C: Imaging:			
- biliary dilatation OR/AND	VEC	NO	
- evidence of etiology (stricture, stone etc)	YES	NO	
One "NO" is present = Acute cholangitis is NOT present = assess cholestasis!			

# If acute cholangitis is present = go to RANDOMIZATION, GROUP A!

Cholestasis			
Imaging signs AND (gallbladder stones / sludge OR dilated CBD OR CBD stone)	YES	NO	
Elevated liver function tests (LFTs) (ALT, ALP and serum bilirubin >1.5xULN)	YES	NO	
One "NO" is present = Cholestasis is NOT present = exclude (GROUP C)!			

## If cholestasis is present = go to RANDOMIZATION, GROUP B!

## **RANDOMIZATION:**

All inclusion criteria met + no exclusion criteria present?	YES / NO
If "YES" = RANDOMIZE!	
Acute cholangitis present?	YES / NO
If "YES" = GROUP A	
Cholestasis present?	YES / NO
If "YES" = GROUP B	

Randomization number:	

(two-digit centrum-ID - one-letter group identifier - three-digit randomization number)

I/B: <u>Assessment:</u>		
Complaints start:	hours	
❖ SEVERITY OF PAIN	N: 1 (none) to 10 (maximum):	
Ethanol: Y / N Medications:	Quantity/day:	
Cholecystectomy: Past medical history:	Azathioprine Opioids: Furosemid: Enalapril: Sulfasalazine: Sulphametoxazole/Trimethroprim: Tetracycline: Steroids: Oral contraceptives:  Gallbladder stones: Biliary colic: Pancreatitis:	Y / N Y / N
ASA 2 - P ASA 3 - P ASA 4 - P	2 3 4 5  Normal healthy patient ration with mild systemic disease with no functional limit ration with moderate systemic disease with functional limit ration with severe systemic disease that is a constant threa rational patient who is not expected to survive another 2	tations mitations t to life
PHYSICAL EXAMINAT	ION:	
Blood pressure:	Hgmm	
Heart rate: T axill.: Resp. freq.: Abdominal Abdominal guar	°C / min tenderness: Y/N	
Comorbidity:		
<ul> <li>heart failure</li> </ul>	Farction or stroke or periferial vascular disease  ork severity:  A I.  A II.  A III.	Y / N Y / N Y / N Y / N
	/ injury (renal failure)	Y / N Y / N

#### **BMI**:

Patient height:	_m	
weight:	_ kg	BMI (kg/m²):

## **ABDOMINAL ULTRASOUND ON ADMISSION (1.):**

#### Gallbladder:

• Stones: yes - sludge - none

### Bile ducts:

- Intrahepatic bile duct dilatation:mild moderate severe
- CBD diameter: \_\_\_\_\_ mm or N/A
- CBD stones: Y / N or N/A

#### Pancreas:

- visible / not visible
- ullet Pancreas oedema: Y/N

inhomogenity: Y/N

pancreas enlargement: Y/N

• Peripancreatic fluid collection: Y/N

Pancreatogen ascites:
 Y / N

### Iv. Fluids:

Before ERCP: \_\_\_ml
First 24 hours: \_\_\_ml

Type of solution: crystalloid / colloid

Laboratory tests:		
WBC	bilirubin	
Hgb	AST	
Htk	ALT	
blood sugar	GGT	
UN	AP	
Creatinie	Amylase	
Na	or lipase	
K	CRP	
Ca	Procalcitonine	

O <sub>2</sub> saturation breath rate	O <sub>2</sub> saturation	breath rate	
---------------------------------------	---------------------------	-------------	--

**Blood gas (Astrup):** 

ONLY if O<sub>2</sub> sat is below 90% OR the breath rate is above 20/min pH \_\_\_\_\_ PaO<sub>2</sub> \_\_\_\_\_

# **ORGAN FAILURE:**

Marshall score  $\geq 2$  for at least one of three organ systems: Y / N

Marshall scoring system	Score				
Organ system	0	1	2	3	4
Respiratory (PaO <sub>2</sub> /FiO2)	> 400	301-400	201-300	101-200	≤ 100
Renal (serum creatinine, $\mu$ mol/1)*	≤ 134	135-169	170-310	311-439	> 439
Cardiovascular (sytolic BP,	> 90	< 90	< 90	< 90,	< 90,
mmHg)**		Fluid responsive	Not fluid responsive	pH < 7.3	pH < 7.2
For non-ventilated patients, the $FiO_2$ can be estimated from below:					
Supplemental Oxygen (l/min)	FiO <sub>2</sub> *A score for patients with pre-existing chronic				
Room air	21%	renal failure depends on the extent of further deterioration of baseline renal function. No			

Supplemental Oxygen (l/min)	FiO <sub>2</sub>	*A score for patients with pre-existing chronic
Room air	21%	renal failure depends on the extent of further deterioration of baseline renal function. No formal correction exists for a baseline serum
2 - 3	25%	creatinine $\geq 134 \ \mu mol/l \ or \geq 1.4 \ mg/dl$
4 - 5	30%	**Off inotropic support. For patients with the need for inotropic catecholamine support, a
6 - 8	40%	Marshall score of 2 is appointed for cardiovascular system and dependent on the pH
9 - 10	50%	a Marshall score of 3 or 4 can be appointed

## **SIRS:**

SIRS				
Heart rate >90/min	YES			
Core temperature <36 °C or >38 °C	YES			
WBC <4 or >10 G/l	YES			
Respiratory rate >20/min	YES			
SIRS present if ≥2 "YES"				

)

# **BISAP:**

BISAP score	1 point for each:
Urea nitrogen >25 mg/dl	YES
Impaired mental status	YES
SIRS present	YES
Age >60 years	YES
Pleural effusion present	YES
Sum of points	

# II. <u>ERCP</u>

Name of endoscopist:					
Date:	_ Time:_	<u>:</u>	Hours af	fter admission:	
Duration of procedure: (scope insertion to extra		15-30 min	>30 min		
Premedication: Y / N	Nalbup Midazo Fentan	olam: yl: an:	Y / N Y / N Y / N Y / N		
Difficult biliary canulati	on: > 5 atte	empts / > 5	mins		
CBD diameter:Stone impacted in papill CBD stones: Sludge in CBD: Papillary oedema: Duodenal oedema: Lacerated orifice: Juxtapapillary diverticul Number of pancreatic grancreatic injections Pancreatic acinarization Pancreas divisum: Successful PD stent if at	a um: uidewire manip		1 / ≥2	Size:	mm
PD stent implanted: PD stent outer end:	tempted:		or 5 cm		
Biliary EST: Conventional sphinctero Precut papillotomy:	dle knife: ecut:	Y / N Y / N Y / N Y / N Y / N	Y / N Y / N Y / N Y / N ation: Y / N		

#### Schutz degree of difficulty: 1 2 3 4 5

Grade 1: Simple diagnostic ERCP (standard diagnostic cholangiogram)
Grade 2: Simple therapeutic ERCP

(standard biliary sphincterotomy, removal of 1-2 small CBD stones (<1 cm), nasobiliary catheter)

**Grade 3: Complex diagnostic ERCP** 

(diagnostic cholangiogram, Billroth II anatomy, biliary cytology)

**Grade 4: Complex therapeutic ERCP** 

(More than 2 or large ≥1 cm CBD stones, cystic duct stone removal, CBD dilation or stenting)

**Grade 5: Very advanced ERCP** 

(precut BS, stone removal with ML, intrahepatic stone removal, Billroth II anatomy)

#### **Subjective difficulty:**

Assessed?: Y / N

**Subjective difficulty of ERCP:** 1 (very simple) to 10 (extremely difficult):

#### **ERCP COMPLICATIONS**

Bleeding: Y / N

Severity: Mild / Moderate / Severe

Endotherapy:

\_\_\_\_

Perforation: Y / N

Type (or Stapfer classification):

#### Bleeding as a complication of ERCP (Cotton classification):

"mild": Hb decreases less than 3 g/dL, no transfusion necessary

"moderate": transfusion of  $\leq 4 \text{ RBC}$  units, no surgery nor arteriography

"severe": transfusion of at least 5 RBC units or surgery or angiographic intervention

## Perforation as a complication of ERCP (Stapfer classification):

"type I": duodenal perforation (lateral or medial wall) / endoscope related

<sup>&</sup>quot;type II": periampullary / sphincerotomy related

<sup>&</sup>quot;type III": ductal or duodenal perforations because of endoscopic instruments

<sup>&</sup>quot;type IV": guidewire related perforation with presence of retroperitoneal gas in imaging

# III. <u>24 HOURS AFTER ERCP</u>

Intensive care unit Y/N	
Blood pressure:	/Hgmm
Heart rate:/ mir	
Γ axill.:°C	
Antibiotics: Y /	N
Intent: Prof	lactic / therapeutic
Specify name and dose	:
Indication:	
SIRS assessed?: SIRS present?:	Y / N Y / N
Organ failure assessed?: Organ failure presen	

## **GLASGOW PROGNOSTIC SCORE (WITHIN 48 HOURS):**

SEVERITY OF PAIN: 1 (none) to 10 (maximum):

SCORE	VALUE	YES
Age	>55 years	
pO <sub>2</sub> (arterial)	<8 kPa (60mmhg)	
Albumine	<32 g/l	
Calcium	<2 mmol/l	
WBC	>15 x10 <sup>9</sup> /l	
LDH	>600 U/l	
Glucose	>10 mmol/l (no diabetic hx)	
Urea	>16 mmol/l	
Pancreatitis is		

Intensive care unit Y / N	intensive care unit	Y / N	10
---------------------------	---------------------	-------	----

# **Nutritional assessment:**

- $\bullet$  oral feeding can be restarted?  $\;\;Y\;/\;N\;$
- enteral feeding needed? Y / N

• NJ

Y / N

• other forms of feeding? Y / N

• NG

o please specify:

Y / N

## **PHYSICAL EXAMINATION:**

Blood pressure:		/		Hgmm
Heart rate:	_/ min			
Temperature:		_°C		
Resp. freq.:	_/ min			
Bowel sounds	absent	_	diminished	– normal
Abdominal tenderness Y	/ N			
Abdominal guarding Y / 1	N			

Laboratory tests:		3.
WBC	Amylase	
Hgb	CRP	
Htk	Creatinine	

## **SIRS:**

SIRS	
Heart rate >90/min	YES
Core temperature <36 °C or >38 °C	YES
WBC <4 or >10 G/l	YES
Respiratory rate >20/min	YES
SIRS present if ≥2 "YES"	

## **ORGAN FAILURE:**

Marshall score ≥2 for at least one of three organ systems:

Y / N

Marshall scoring system	Score				
Organ system	0	1 2 3			4
Respiratory (PaO <sub>2</sub> /FiO2)	> 400	301-400	201-300	101-200	≤ 100
Renal (serum creatinine, µmol/1)*	≤ 134	135-169	170-310	311-439	> 439
Cardiovascular (sytolic BP,	> 90	< 90	< 90	< 90,	< 90,
mmHg)**		Fluid responsive	Not fluid responsive	pH < 7.3	pH < 7.2
For non-ventilated patients, the F	iO2 can be e	stimated fron	n below:		
Supplemental Oxygen (l/min)	FiO <sub>2</sub>		r patients with		
Room air	21%	renal failure depends on the extent of further deterioration of baseline renal function. No formal correction exists for a baseline serum			
2 - 3	25%	creatinine $\geq 134 \ \mu mol/l \ or \geq 1.4 \ mg/dl$			
4 - 5	30%	**Off inotropic support. For patients with the need for inotropic catecholamine support, a			
6 - 8	40%	Marshall score of 2 is appointed for cardiovascular system and dependent on the pH a Marshall score of 3 or 4 can be appointed			-
9 - 10	50%				

## V. <u>72 HOURS AFTER ERCP:</u>

Intensive care unit

Y / N

SIRS assessed?:
SIRS present?:
Y / N

Organ failure assessed?:
Organ failure present?:
Y / N

SEVERITY OF PAIN: 1 (none) to 10 (maximum):

#### **ABDOMINAL ULTRASOUND (2.):**

#### Gallbladder:

Stones: yes - sludge - none
 Pericholecystic fluid: Y / N

#### Bile ducts:

- Intrahepatic bile duct dilatation:mild moderate severe
- CBD diameter: \_\_\_\_\_ mm or N/A
   CBD stones: \_\_\_\_\_ Y / N or N/A

#### Pancreas:

- visible / not visible
- Pancreas: oedema: Y / N inhomogenity: Y / N pancreas enlargement: Y / N
   Peripancreatic fluid collection: Y / N
   Pancreatogen ascites: Y / N

Peripancreatic fluid collection: Y / N

## VI. 72 - 96 HOURS AFTER ERCP:

## **ONLY IF:**

- severe ABP
- fail to respond conservative treatment
- clinically deteriorating

Abdominal CT scan (3-5 days):	- performed'?	Y / N	
Performed hours after ra	andomization		
Balthazar score: $A / B / C / D / E$			
A: Normal B: "intrinsic pancreatic changes"			
C: "Intrinsic and extrinsic pancreation			atic soft mass"
D: "Extrinsic pancreatic changes with E: "Multiple or extensive extrapance			

% of necrosis (no contrast enhancement): none / <33% / 33-66% / >66%

Local complications: Y / N

Systemic complications: Y/N

# VII. OVERALL OUTCOME

Total le	ength of stay:	days	(ICU length of stay:	days)
Multi o Severe ≫ □ □	rgan failure:	ntilation	persistent	
(tick ap	opropriately) Shock Sepsis Renal failure ARDS / respira Heart failure / DIC / coagulop Hypocalcaemia	hypotension pathy		
(tick ap	Pancrearic pset Acute necrotic Walled off nec	udocyst collection rosis cted necrosis / phlegn	n without tendency of spontan	eous resolution
Mortal	lity:	Y / N	Date of death:	
Cause	of death:			
Antibio	Specify:	active substance atration (e.g. 10%, 1g/	re: dose (gram,n'/2ml, etc.) how indication:	many times/day
Jejuna	l feeding:	Y/N		,
CT sco	re:	_		
Max. C	CRP:	_		
Surgery:		Y / N		